Clinical trials: Immune
Mesothelioma
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
The UK has the highest incidence of mesothelioma. The incidence has risen by 497% since the late 1970's and is increasing worldwide due to continued mining and use of asbestos.
- Trial name
- CONFIRM (NCT03063450)
- Testing
- Nivolumab
- Where
- 24 sites in United Kingdom
- Volunteers
- 332 people
- Sponsor
- University of Southampton
HIV Infections, Acquired Immunodeficiency Syndrome
Effectiveness of Structured Ecosystems Therapy for Reducing HIV Risk Behaviors and Improving Treatment Adherence in HIV Infected Men Released From Prison
This study will evaluate the effectiveness of Structured Ecosystems Therapy (SET), a form of therapy that includes family and caregivers, at reducing HIV transmission risk behaviors and improving treatment adherence in HIV…
- Trial name
- NCT00344591
- Testing
- Structured Ecosystems Therapy (SET), Individually tailored intervention
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- University of California, San Francisco
HIV Infection, Sexual and Reproductive Health
PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.
The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period.
- Trial name
- PtC (NCT06807736)
- Testing
- Cabotegravir long-acting, Tenofovir emtricitabine, Dapivirine containing vaginal ring
- Where
- South Africa
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Desmond Tutu HIV Foundation
Human Immunodeficiency Virus (HIV) Infection
Strategies to AchieVe Viral Suppression for Youth With HIV
Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other…
- Trial name
- SAVVY (NCT06886971)
- Testing
- The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Johns Hopkins University
Thyroid Eye Disease
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
- Trial name
- NCT05524571
- Testing
- Batoclimab
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- Immunovant Sciences GmbH
HIV Infections
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
- Trial name
- NCT00675844
- Testing
- Elvucitabine
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Lung Cancer Stage IV, Lung Cancer, Non-small Cell
Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Immune-checkpoint inhibitors have recently become available as a new therapy for a variety of cancers. This drugs function by boosting the anti-cancer immune response, but unfortunately, may cause off-target, non-specific immune…
- Conditions
- Lung Cancer Stage IV, Lung Cancer, Non-small Cell, Hepatitis
- Trial name
- NCT04595734
- Testing
- No intervention due to observational methods of study
- Where
- 3 sites in Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Multiple Sclerosis
Thalamic Nuclei Volumes in Multiple Sclerosis
The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly…
- Trial name
- THALNUC-MS (NCT05002764)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Bordeaux
Covid19, SARS-CoV Infection
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
The co-primary objectives of this study are to: 1. Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection 2.
- Trial name
- START (NCT04573634)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jill M Kolesar
Chronic Lymphocytic Leukemia
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
The treatment combination of Rituxan® (rituximab) and fludarabine has previously been reported to produce a high percentage of responses with less toxicity than other combination treatments.
- Trial name
- NCT00078234
- Testing
- Oblimersen-rituximab-fludarabine
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genta Incorporated
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire
Multiple Myeloma
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to evaluate the effectiveness and side effects of the bortezomib, lenalidomide and dexamethasone combination in relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT00378209
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Giant Cell Arteritis
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.
Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA).
- Trial name
- NCT03244709
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Hospital of Prato
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Survivors Uniting for Remote Guided Exercise
The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among…
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior
- Trial name
- SURGE (NCT07290309)
- Testing
- Virtually Supervised Exercise Sessions, Asynchronous Group
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Colorado State University
Hepatic Encephalopathy
Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
The primary purpose of this study is to evaluate the safety and effectiveness of Ammonul® in subjects who become hospitalized with Grade 3 or 4 hepatic encephalopathy (HE).
- Trial name
- NCT00597909
- Testing
- sodium phenylacetate and sodium benzoate injection 10% / 10%
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Amgen
HIV Infections
Raltegravir Insulin Sensitivity Study
The purpose of the study is to look at the effects of two different HIV medications on the body's response to insulin (a hormone that regulates blood sugar levels).
- Trial name
- NCT00531999
- Testing
- Raltegravir then lopinavir/ritonavir, Lopinavir/ritonavir then raltegravir
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
Neurological Autoimmune Diseases
IA or PE - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases.
- Trial name
- NCT04687332
- Testing
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- University Medical Center Mainz
Infection, Human Immunodeficiency Virus, HIV Infections
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements.
- Trial name
- NCT02478463
- Testing
- Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance
The goal of this Phase 1 clinical trial is to learn whether all-trans retinoic acid (ATRA) combined with tislelizumab is safe and tolerable in adults with EGFR-mutant non-small cell lung cancer (NSCLC).
- Trial name
- A Phase 1 Clin (NCT07842887)
- Testing
- All-trans retinoic acid, Tislelizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT01659021
- Testing
- Idelalisib, Ofatumumab
- Where
- 80 sites in United States, Australia and 9 more
- Volunteers
- 261 people
- Sponsor
- Gilead Sciences